Overactive Bladder Syndrome Clinical Trial
Official title:
The Effect of Pulse Rate Changes on Clinical Outcome in Sacral Neuromodulation
Objectives: To evaluate the effect of pulse rate changes on the clinical response and
stimulation related pain symptoms in sacral neuromodulation (SNM) treatment.
Materials and Methods: This pilot study evaluated the effect of 4 different pulse rates
(5.2Hz-10Hz-21Hz-40Hz) in patients with suboptimal response to SNM. The effect of each
frequency was evaluated over test period of 6 days. To avoid carry over effect, stimulation
was kept off for 24 hours between consecutive test periods. The last 3 days of every test
period, a voiding diary (VD) and questionnaire was filled in. The changes on clinical
response and pain symptoms were compared between the four pulse-rates using multivariate
analysis.
Results: Fifty patients were included of which 40 (80%) were female. Mean age was 55.5yr (SD
12.3). Forty-one patients (82%) had overactive bladder symptoms and 9 (18%) had chronic
non-obstructive urinary retention. No significant difference was found regarding clinical
outcome (VD and questionnaire) between the different pulse rates. Furthermore, none of the
four pulse rates was significantly related to the occurrence of SNM-related pain. However,
on individual basis, patients appear to benefit from changing the pulse rate concerning both
treatment efficacy and stimulation related pain.
Conclusions: On group level, none of the four pulse rates in this study appears to have a
significantly different effect on clinical outcome or SNM-related pain. However, a
tailor-made approach for optimizing treatment efficacy by changing the pulse rate might be
useful.
n/a
Intervention Model: Single Group Assignment, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02540707 -
Comparisons of the Effects of Solifenacin Versus Mirabegron on Autonomic System, Arterial Stiffness and Psychosomatic Distress and Clinical Outcomes
|
Phase 4 | |
| Not yet recruiting |
NCT05977634 -
Transcutaneous Tibial Nerve Stimulation for Idiopathic Overactive Bladder
|
N/A | |
| Not yet recruiting |
NCT06438861 -
Role of Combination Therapy in Women With Refractory Overactive Bladder
|
N/A | |
| Completed |
NCT01114412 -
Basic Sensations Coming From the Bladder
|
||
| Recruiting |
NCT06045728 -
Telerehabilitation for Overactive Bladder Syndrome in Obese Women
|
N/A | |
| Recruiting |
NCT03952299 -
Oxybutynin for Post-surgical Bladder Pain and Urgency
|
Phase 3 | |
| Active, not recruiting |
NCT03758235 -
Overactive Bladder Syndrome: Incobotulinumtoxin Versus Onabotulinumtoxin
|
Phase 3 | |
| Completed |
NCT01912885 -
Comparison of Posterior Tibial Nerve Electrical Stimulation Protocols for Overactive Bladder Syndrome
|
N/A | |
| Completed |
NCT04300400 -
Treatment of the Overactive Bladder Syndrome: A Delphi Study
|
||
| Recruiting |
NCT04982120 -
Use of Repris Needle in Bladder Injection
|
N/A | |
| Completed |
NCT06123364 -
Extracorporeal Magnetic Innervation in Combination With Mirabegron in the Treatment of Overactive Bladder
|
N/A | |
| Recruiting |
NCT06088394 -
Effect of Acupuncture Augmented With Pelvic Floor Exercises on Overactive Bladder
|
N/A | |
| Recruiting |
NCT05221021 -
Vaginal Estradiol vs Oral Beta-3 Agonist for Overactive Bladder Syndrome
|
Phase 4 | |
| Terminated |
NCT04256876 -
TTNS Versus Sham Therapy for Children With iOAB (TaPaS Part I)
|
N/A | |
| Not yet recruiting |
NCT03331081 -
Effects of Bladder Training and Pelvic Floor Muscle Training on the Symptomatology of Overactive Bladder Syndrome
|
N/A | |
| Recruiting |
NCT04873037 -
BTL Emsella Chair Versus Sham for the Treatment of Overactive Bladder
|
N/A | |
| Completed |
NCT02024945 -
Efficacy, Tolerability and Impact on Quality of Life of Propiverine in Patients With Overactive Bladder Syndrome
|
Phase 4 | |
| Completed |
NCT00546637 -
Fesoterodine "add-on" Male Overactive Bladder Study
|
Phase 3 | |
| Not yet recruiting |
NCT06143397 -
Effect of TTNS and PNS on Neurogenic Overactive Bladder Symptoms in Female Patients With Multiple Sclerosis.
|
N/A | |
| Recruiting |
NCT03044912 -
Therapeutic Efficacy and Safety of Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan
|
Phase 3 |